Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Identifying Specific Receptor Mediated Mechanisms Underlying the Delivery of Nanoparticle Vehicles across the Blood Brain Barrier for the Treatment of Glioblastoma

FY 2019-20

Summary
Glioblastoma is the most common and aggressive brain tumor, accounting for 45% of malignant tumors in the central nervous system. First line treatment for glioblastoma is surgical resection followed by toxic doses of chemotherapy. Chemotherapy is used to shrink or eliminate cancer cells before and after surgery with the goal of reducing trauma from surgery and preventing cancer recurrence, respectively. Utilizing chemotherapy for these purposes in glioblastoma is difficult because chemotherapy delivers poorly to the brain. Chemotherapy delivery to the brain is limited by the blood brain barrier, a specialized network of blood vessels partitioning blood from the brain tissue environment. Nanotechnology provides an effective platform for enhancing chemotherapy delivery to the brain. Liposomes, nanoparticles composed of lipids, were first developed to exploit the passive transport of lipids across the blood brain barrier. This method enhances delivery to the brain relative to free drugs but overall delivery is low, numbering at 4% of the injected dose-a therapeutic quantity is 10% for solid tumors. This led to the addition of blood brain barrier receptor ligands to liposomes and other nanoparticles to increase delivery. The most effective ligands used to date are transferrin and insulin as their receptors are ubiquitous on the blood brain barrier. However, delivery only increases to 5% of the injected dose with these ligands. These approaches are deficient because they target receptors and transport mechanisms found widely across the body and not uniquely at the blood brain barrier. The objective of this project is to identify receptors specific to the blood brain barrier that transport nanoparticles with the goal of elucidating a blood brain barrier specific receptor and transport mechanism involved in nanoparticle uptake to guide brain targeted nanoengineering.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
415778
Name
Ahmed Sara E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Identifying Specific Receptor Mediated Mechanisms Underlying the Delivery of Nanoparticle Vehicles across the Blood Brain Barrier for the Treatment of Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Blood Brain Barrier; Drug Delivery; Glioblastoma; Nanoparticle Drug Vehicle
Abstract
Glioblastoma is the most common and aggressive brain tumor, accounting for 45% of malignant tumors in the central nervous system. First line treatment for glioblastoma is surgical resection followed by toxic doses of chemotherapy. Chemotherapy is used to shrink or eliminate cancer cells before and after surgery with the goal of reducing trauma from surgery and preventing cancer recurrence, respectively. Utilizing chemotherapy for these purposes in glioblastoma is difficult because chemotherapy delivers poorly to the brain. Chemotherapy delivery to the brain is limited by the blood brain barrier, a specialized network of blood vessels partitioning blood from the brain tissue environment. Nanotechnology provides an effective platform for enhancing chemotherapy delivery to the brain. Liposomes, nanoparticles composed of lipids, were first developed to exploit the passive transport of lipids across the blood brain barrier. This method enhances delivery to the brain relative to free drugs but overall delivery is low, numbering at 4% of the injected dose-a therapeutic quantity is 10% for solid tumors. This led to the addition of blood brain barrier receptor ligands to liposomes and other nanoparticles to increase delivery. The most effective ligands used to date are transferrin and insulin as their receptors are ubiquitous on the blood brain barrier. However, delivery only increases to 5% of the injected dose with these ligands. These approaches are deficient because they target receptors and transport mechanisms found widely across the body and not uniquely at the blood brain barrier. The objective of this project is to identify receptors specific to the blood brain barrier that transport nanoparticles with the goal of elucidating a blood brain barrier specific receptor and transport mechanism involved in nanoparticle uptake to guide brain targeted nanoengineering.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ahmed, Sara E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2019-20) | Canada Spends